Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

A MultIceNTER Phase I Peptide VaCcine Trial to Exploit NeoePitope-Specific T Cells for the Treatment of H3-Mutated Gliomas – (INTERCEPT H3) Ended

2024-514840-97-00 glioma WHO grade IV (C71.1-9 according to ICD-10 classi 3 2023-02-15
Roll-over study for patients who have completed a prior Novartis sponsored sabatolimab (MBG453) study and are judged by the investigator to … Ended

2024-515281-14-00 intermediate, high or very high risk MDS in adult patie 4 2023-02-13
Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarci… Ended

2024-513610-34-00 HER2-positive, localized esophagogastric adenocarcinoma 4 2023-02-13
Pembrolizumab Monotherapy versus Sacituzumab Govitecan in Combination with MK‑3475 for PD-L1 TPS ≥50% Metastatic NSCLC Ended

2023-503501-11-00 Metastatic Non-small Cell Lung Cancer 5 2023-02-09
EFFICACY AND SAFETY TRIAL OF EPCORITAMAB WITH OR WITHOUT LENALIDOMIDE AS FIRST LINE THERAPY FOR SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMA. Ended

2023-504832-16-00 DIFFUSE LARGE B CELL LYMPHOMA 4 2023-01-24
Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma Ended

2024-517205-82-00 adrenocortical carcinoma 4 2023-01-20
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated … Ended

2023-504027-78-00 Previously Untreated Locally Advanced or Metastatic Uro 4 2023-01-13
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety tolerability, pharmacokinetics… Ended

2023-510061-10-00 Clear cell renal cell carcinoma (ccRCC, first-, second- 3 2023-01-09
A study to investigate subcutaneous isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and/or … Ended

2023-508870-27-00 Cancer - Relapsed/refractory multiple myeloma 4 2023-01-04
Anti-PD-1 re-challenge after immune priming by ipilimumab and immune boosting by radiotherapy in advanced NSCLC. Ended

2022-500713-79-00 Patients with advanced NSCLC who have progressed after 10 2023-01-03
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303) Ended

2024-512915-33-00 Metastatic Colorectal Cancer 5 2022-12-22
RESTORING SENSITIVITY TO IMMUNOTHERAPY IN ADVANCED TRIPLE NEGATIVE BREAST CANCER EXPLOITING CERALASERTIB PRIMING FOLLOWED BY COMBINED DURVAL… Ended

2024-513721-23-00 ADVANCED TRIPLE NEGATIVE BREAST CANCER 4 2022-12-15
Pembrolizumab for locally advanced, irresectable, non-metastatic dMMR colorectal cancers. The PUMA study. Ended

2023-509707-32-00 Locally advanced, irresectable dMMR colorectal cancers 4 2022-12-13
An Interventional and Translational Study investigating Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With M… Ended

2024-510837-16-00 locally-advanced and unresectable or metastatic NSCLC w 4 2022-12-13
Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mut… Ended

2024-511548-19-00 Pancreatic Ductal Adenocarcinoma 1 2022-12-13
Treatment pause versus treatment continuation in good or intermediate risk with only one adverse prognostic factor in mRCC patients that has… Ended

2024-514644-93-00 Metastatic renal cell carcinoma (mRCC) with a good or o 5 2022-12-09
A PHASE 1/2, DOSE AND SCHEDULE EVALUATION STUDY TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN ADMINISTERED IN COMB… Ended

2024-516147-32-00 Relapsed/refractory multiple myeloma 9 2022-12-06
PH2a, Platform Study of Novel Immunotherapy Combinations in Participants with Previously Untreated, Advanced/Metastatic NSCLC Ended

2023-505057-40-00 Lung Cancer, Non-Small Cell 4 2022-12-02
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic … Ended

2023-509825-38-00 Metastatic Non–Small Cell Lung Cancer 5 2022-12-01
Olaparib and durvalumab (MEDI4736) in patients with metastatic pancreatic cancer and DNA Damage Repair genes alterations Ended

2024-510970-26-00 Metastatic pancreatic cancer 4 2022-11-28
Study of neoadjuvant patritumab deruxtecan with or without endocrine therapy in previously untreated patients – VALENTINE trial Ended

2023-503403-28-00 treatment naïve patients with HR+/HER2-negative high-ri 4 2022-11-25
A global study to evaluate transarterial chemoembolization(TACE) in combination with durvalumab, tremelimumab +/-lenvatinib therapy compared… Ended

2023-508701-24-00 Locoregional Hepatocellular Carcinoma (HCC) 5 2022-11-21
A phase I trial of IMA970A plus Montanide in combination with Durvalumab (anti-PD-L1) in patients with very early, early and intermediate st… Ended

2024-518298-33-00 Hepatocellular carcinoma 3 2022-11-21
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With N… Ended

2024-510947-71-00 Chronic Myeloid Leukemia 5 2022-11-21